McNeeley S G, Schinfeld J S, Stovall T G, Ling F W, Buxton B H
Department of Obstetrics and Gynecology, University of Tennessee College of Medicine, Memphis.
Int J Gynaecol Obstet. 1991 Mar;34(3):253-6. doi: 10.1016/0020-7292(91)90359-d.
The effect of medroxyprogesterone acetate 10 mg BID alone, conjugated estrogens alone or in a combination regimen for the prevention of osteoporosis was determined in 36 postmenopausal women using single photon densitometry. No significant differences in cortical or trabecular bone mass over time were detected in women between the three treatment groups, although a slight increase in bone mass was noted in women with the combined therapy. Medroxyprogesterone acetate appears efficacious in preventing postmenopausal osteoporosis, and may be especially useful in women with contraindications to estrogen replacement therapy.
采用单光子骨密度测定法，对36名绝经后女性进行研究，以确定单独使用10毫克醋酸甲羟孕酮每日两次、单独使用结合雌激素或联合用药方案预防骨质疏松症的效果。三个治疗组女性的皮质骨或小梁骨量随时间均未发现显著差异，不过联合治疗的女性骨量略有增加。醋酸甲羟孕酮似乎对预防绝经后骨质疏松症有效，对有雌激素替代疗法禁忌证的女性可能尤其有用。
